Clinical study of Mogadon

Publisher Website
Google Scholar
Abstract
A new experimental anticonvulsant, Mogadon, an analogue of Librium, was studied in 108 patients in clinical trials over a 4 year period. All patients were intractable epileptics whose seizures remained uncontrolled with any combination of standard anticonvulsants in common use. Of the 108 patients, 47, or 43%, evidenced seizure improvement of 30% or more when Mogadon was administered. In some, improvement was dramatic with complete seizure control for the 6 to 24 months of follow-up. Twenty-five patients evidenced breakthrough with recurrence of seizures in 2 to 6 months despite continued use of the drug. Myoclonic, minor motor, akinetic, and psychomotor seizures were most responsive. Petit mal attacks in 3 patients were aggravated even when associated grand mal seizures decreased in frequency. A small number of patients could not tolerate the drug even in the initial dosage because of lethargy and ataxia. In general, tolerance was good and clinical toxicity was considered no greater than with primidone or diphenylhydantoin. The patients were carefully followed with blood, renal, and liver function studies without evidence of serious toxicity. Mogadon, therefore, is a safe and effective anticonvulsant worthy of trial, particularly in patients with intractable epilepsy.

This publication has 0 references indexed in Scilit: